MedTrace Logo

Usability Study of CEREBO® - A Novel Non-invasive Intracranial Bleed Detector

NCT05340114 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2022-04-21

No results posted yet for this study

Summary

Traumatic Brain Injury (TBI) is the leading cause of death and disability across the globe. Time from injury to treatment is the most critical factor that determines the patient's recovery. Mild TBI with no apparent symptoms are often left undiagnosed, thus delaying the treatment and hence recovery. CEREBO® is a non-invasive, rapid, near-infrared based, point-of-care device that can detect an intracranial bleed at an early stage.

Conditions

Interventions

DEVICE

CEREBO®

Near-infrared based point-of-care portable intracranial hematoma detector

Sponsors & Collaborators

  • Bioscan Research Pvt. Ltd.

    lead INDUSTRY

Principal Investigators

  • Dr. Jaimin Shah · Civil Hospital India

Study Design

Allocation
NA
Purpose
DEVICE_FEASIBILITY
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-04-25
Primary Completion
2023-04-30
Completion
2023-05-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05340114 on ClinicalTrials.gov